Compare UPWK & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UPWK | CAPR |
|---|---|---|
| Founded | 1998 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 2018 | 2011 |
| Metric | UPWK | CAPR |
|---|---|---|
| Price | $10.93 | $31.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 8 |
| Target Price | $22.73 | ★ $44.63 |
| AVG Volume (30 Days) | ★ 2.9M | 1.3M |
| Earning Date | 05-04-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.84 | N/A |
| Revenue | ★ $787,784,000.00 | N/A |
| Revenue This Year | $9.10 | N/A |
| Revenue Next Year | $13.60 | $35.83 |
| P/E Ratio | $13.02 | ★ N/A |
| Revenue Growth | ★ 2.40 | N/A |
| 52 Week Low | $10.52 | $4.30 |
| 52 Week High | $22.84 | $40.37 |
| Indicator | UPWK | CAPR |
|---|---|---|
| Relative Strength Index (RSI) | 34.86 | 60.07 |
| Support Level | N/A | $22.09 |
| Resistance Level | $13.97 | $36.49 |
| Average True Range (ATR) | 0.48 | 1.97 |
| MACD | 0.12 | -0.12 |
| Stochastic Oscillator | 19.81 | 93.06 |
Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with skilled independent professionals. The company develops platform for hiring and freelancing purposes and connects businesses with AI-enabled talent across every on-demand work type, including freelance, agency, fractional, and payrolled. The business generates revenue from Talent and Clients across the USA, India, Pakistan, the Philippines and the rest of the world. Maximum revenue of the company is derived from Talent segment.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.